Literature DB >> 24595127

Prostate cancer: treatment sequencing for CRPC--what do we know?

Axel Heidenreich1, Daniel Porres1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24595127     DOI： 10.1038/nrurol.2014.36

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Karim Fizazi; Howard I Scher; Arturo Molina; Christopher J Logothetis; Kim N Chi; Robert J Jones; John N Staffurth; Scott North; Nicholas J Vogelzang; Fred Saad; Paul Mainwaring; Stephen Harland; Oscar B Goodman; Cora N Sternberg; Jin Hui Li; Thian Kheoh; Christopher M Haqq; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-09-18       Impact factor: 41.316

2.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

3.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

4.  Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.

Authors:  Meng-Lei Zhu; Craig M Horbinski; Mark Garzotto; David Z Qian; Tomasz M Beer; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-08-31       Impact factor: 12.701

Review 5.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.

Authors:  Andres Jan Schrader; Martin Boegemann; Carsten-H Ohlmann; Thomas J Schnoeller; Laura-Maria Krabbe; Turkan Hajili; Florian Jentzmik; Michael Stoeckle; Mark Schrader; Edwin Herrmann; Marcus V Cronauer
Journal:  Eur Urol       Date:  2013-07-02       Impact factor: 20.096

8.  Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Authors:  J Mezynski; C Pezaro; D Bianchini; A Zivi; S Sandhu; E Thompson; J Hunt; E Sheridan; B Baikady; A Sarvadikar; G Maier; A H M Reid; A Mulick Cassidy; D Olmos; G Attard; J de Bono
Journal:  Ann Oncol       Date:  2012-07-05       Impact factor: 32.976

9.  Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Authors:  Carmel J Pezaro; Aurelius G Omlin; Amelia Altavilla; David Lorente; Roberta Ferraldeschi; Diletta Bianchini; David Dearnaley; Christopher Parker; Johann S de Bono; Gerhardt Attard
Journal:  Eur Urol       Date:  2013-12-17       Impact factor: 20.096

Review 10.  A new trick of an old molecule: androgen receptor splice variants taking the stage?!

Authors:  Zhiyong Guo; Yun Qiu
Journal:  Int J Biol Sci       Date:  2011-07-06       Impact factor: 6.580
  10 in total
  5 in total

1.  Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.

Authors:  Jun Liu; Guojun Jiang; Aiping Yang; Guohui Yang; Wenjuan Yang; Yi Fang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

2.  Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Authors:  Kristell L S Chatalic; Sandra Heskamp; Mark Konijnenberg; Janneke D M Molkenboer-Kuenen; Gerben M Franssen; Marian C Clahsen-van Groningen; Margret Schottelius; Hans-Jürgen Wester; Wytske M van Weerden; Otto C Boerman; Marion de Jong
Journal:  Theranostics       Date:  2016-04-12       Impact factor: 11.556

Review 3.  Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches.

Authors:  Zool Hilmi Awang; Markus Essler; Hojjat Ahmadzadehfar
Journal:  Radiat Oncol       Date:  2018-05-23       Impact factor: 3.481

Review 4.  Improving adenoviral vectors and strategies for prostate cancer gene therapy.

Authors:  Rodrigo Esaki Tamura; Igor Vieira de Luna; Marlous Gomes Lana; Bryan E Strauss
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

5.  Optimized 68Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer.

Authors:  Yitian Wu; Xiaojun Zhang; Ying Zhang; Baixuan Xu; Jiahe Tian; Jinming Zhang
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.